Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenstr m Macroglobulinemia

  • STATUS
    Recruiting
  • End date
    May 29, 2024
  • participants needed
    90
  • sponsor
    Centre Hospitalier Universitaire, Amiens
Updated on 29 May 2021
monoclonal antibodies
bone marrow procedure
cytopenia
monoclonal antibody therapy
monoclonal protein
immunoglobulin

Summary

Waldenstrm Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. This chronic lymphoproliferative disorder requires treatment only in case of symptoms, according to accurate criteria described during the second Workshop on WM i.e. in case of cytopenia, bulky organomegaly, immunological or physicochemical consequences of the presence of IgM in circulating blood. A MYD88 mutation, typically a MYD88(L265P), is found in 90% of WM patients. Other gene abnormalities have been observed, the most frequent is a mutation in the CXCR4 gene. Overall, gene mutations in WM involve only a limited number of signalling pathways, yielding the activation of NFkB, namely : the TLR and MYD88 pathway (with an activation of NFkB and BTK in case of MYD88(L265P) mutation), the BCR pathway (involving btk and associated with activations of both NFkB, and erk akt pathway) and the CXCR4 pathway (CXCR4 is a receptor of CXCL12, it is also associated with activations of ERK/MAPK and PI3K). Abnormalities of some of genes, such as TP53, of the expression of the protein CXCL13 and genes involved in the interleukin 6 secretion have been associated with some clinical characteristics.

The purpose of this project is to define the prognostic role of the detection of circulating tumoral DNA (ctDNA) at the end of treatment for the progression/relapse risk within the first 3 years after the first 6 months of treatment.

Details
Condition Waldenstrom's Disease, Waldenstrom Macroglobulinemia, Lymphoproliferative disorders, Waldenstrom's Macroglobulinemia, Lymphoproliferative Disorder
Treatment Blood sample, Bone marrow sample
Clinical Study IdentifierNCT04893564
SponsorCentre Hospitalier Universitaire, Amiens
Last Modified on29 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient with WM according to diagnostic criteria
Patients with WM followed in one of the centre of North-Western region
Patients requiring first-line or subsequent-line therapy
Patients agreement for giving informed consent
Social insurance system affiliation

Exclusion Criteria

Patients with another chronic B-cell malignancy
patients with other lymphoplasmacytic proliferations
patients with marginal zone lymphoma
Patients with WM and histologic transformation
Absence of informed consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note